Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
78
-
Total 13F shares, excl. options
-
32.6M
-
Shares change
-
-1.55M
-
Total reported value, excl. options
-
$71.3M
-
Value change
-
-$14.4M
-
Number of buys
-
44
-
Number of sells
-
-44
-
Price
-
$2.19
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2019
103 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2019.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 78 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.6M shares
of 108M outstanding shares and own 30.04% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.98M shares), FRANKLIN RESOURCES INC (3.85M shares), Man Group plc (2.06M shares), Rock Springs Capital Management LP (2.03M shares), Sofinnova Investments, Inc. (1.91M shares), VANGUARD GROUP INC (1.87M shares), Vivo Capital, LLC (1.65M shares), Endurant Capital Management LP (1.63M shares), MFN Partners Management, LP (1.5M shares), and FMR LLC (1.37M shares).
This table shows the top 78 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.